EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|February 7, 2004
Clinical comparison pushes AD treatment toward potency chart
Interim data from three studies released at the 62nd annual conferenceof the American Academy of Dermatology support preliminary data presentedlast month demonstrating that tacrolimus ointment (Protopic, Fujisawa) ismore effective than pimecrolimus cream (Elidel, Novartis) in the treatmentof adult and pediatric patients with atopic dermatitis.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Tilrekimig Phase 2 Data Show EASI 75 Gains in Atopic Dermatitis
4
NEA Report Highlights Atopic Dermatitis Care Access Gaps by State
5